RecruitingNCT06188234
The Prescription Patterns and Clinical Efficacy of Tenero Tab/Tenero M SR Tab
Observational Study on the Prescription Patterns and Clinical Efficacy of Tenero Tab/Tenero M SR Tab in Korean Type 2 Diabetes Mellitus Patients
Sponsor
Hanlim Pharm. Co., Ltd.
Enrollment
3,000 participants
Start Date
Dec 27, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This study is to observe the prescription patterns and clinical efficacy of patients prescribed with Tenero Tab/Tenero M SR Tab for diabetes treatment in routine clinical practice.
Eligibility
Min Age: 19 Years
Inclusion Criteria4
- Adults over 19 years of age
- Individuals diagnosed with type 2 diabetes.
- Individuals who, at the clinical discretion, are prescribed Tenero Tab or Tenero M SR Tab for the purpose of diabetes treatment for the first time.
- Individuals who have voluntarily provided written consent to participate in this study.
Exclusion Criteria3
- Pregnant or breastfeeding women.
- Individuals who are contraindicated according to the approved indications of Tenero Tab/Tenero M SR Tab.
- Other cases where the principal investigator and study personnel deem individuals ineligible for participation in this clinical trial.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06188234
Related Trials
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731153 locations
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418115 locations
Project Dulce for Arab Americans With Type 2 Diabetes
NCT055805362 locations
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
NCT038787061 location
Food Insecurity Reduction & Strategy Team
NCT063293751 location